Solvay earns $25M as obesity drug advances

Solvay will garner a $25 million payday from Bristol-Myers Squibb as it advances its obesity therapy, SLV319, into additional mid-stage trials. The experimental drug is a CB1 antagonist, blocking the cannabinoid type 1 receptor in order to reduce the body's demand for food.

- read the AFX report on Solvay

ALSO: Sanofi-Aventis hopes Acomplia, its anti-obesity drug, will be approved by the FDA on or around April 27, 2007. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.